Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edgewise Therapeutics (EWTX) Payables (2020 - 2026)

Edgewise Therapeutics has reported Payables over the past 7 years, most recently at $7.3 million for Q1 2026.

  • Quarterly results put Payables at $7.3 million for Q1 2026, down 17.02% from a year ago — trailing twelve months through Mar 2026 was $7.3 million (down 17.02% YoY), and the annual figure for FY2025 was $6.0 million, up 7.65%.
  • Payables reached $7.3 million in Q1 2026 per EWTX's latest filing, up from $6.0 million in the prior quarter.
  • Across five years, Payables topped out at $8.8 million in Q1 2025 and bottomed at $2.8 million in Q2 2022.
  • Median Payables over the past 5 years was $5.6 million (2024), compared with a mean of $5.7 million.
  • The largest annual shift saw Payables skyrocketed 229.43% in 2022 before it plummeted 34.07% in 2023.
  • Over 5 years, Payables stood at $6.1 million in 2022, then crashed by 34.07% to $4.0 million in 2023, then skyrocketed by 38.61% to $5.6 million in 2024, then increased by 7.65% to $6.0 million in 2025, then grew by 21.43% to $7.3 million in 2026.
  • Business Quant data shows Payables for EWTX at $7.3 million in Q1 2026, $6.0 million in Q4 2025, and $6.2 million in Q3 2025.